Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C. The company will highlight expanded product offerings and other 3D applications in oncology, neuroscience, toxicity screening, and more. Corning experts will be able to speak to these applications, the impact of 3D in research and development and drug discovery, as well as perspectives in disease modeling and high-throughput screening. Discussion topics will include how the use of physiologically relevant 3D cell cultures is facilitating discovery and validation of novel drug targets and accelerating clinical translation of drug candidate screening for safety and efficacy. Spokespeople will be available for tours and to share insights at booth #413. Corning and its customers will also offer several presentations and posters during SLAS including: Presentations and...
Interested in reading more?
Become a Member of
